Boston Partners lowered its stake in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 35.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,305 shares of the medical instruments supplier’s stock after selling 143,587 shares during the period. Boston Partners owned 0.58% of Haemonetics worth $27,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Haemonetics by 1,191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after acquiring an additional 418,470 shares during the last quarter. Bank of America Corp DE purchased a new stake in Haemonetics in the 2nd quarter worth $33,326,000. William Blair Investment Management LLC purchased a new stake in Haemonetics in the 2nd quarter worth $24,906,000. Finally, Bank of New York Mellon Corp purchased a new stake in Haemonetics in the 2nd quarter worth $21,566,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on HAE. Citigroup restated a “market outperform” rating on shares of Haemonetics in a research report on Monday, November 16th. Weiss Ratings upgraded Haemonetics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Mizuho set a $165.00 target price on Haemonetics in a research report on Thursday, November 5th. BTIG Research increased their price target on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, JPMorgan Chase & Co. raised their price target on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.50.
Insider Activity
In related news, CAO Farris Maryanne Maunsell sold 836 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total transaction of $101,147.64. Following the transaction, the chief accounting officer directly owned 5,828 shares in the company, valued at approximately $705,129.72. This represents a 12.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.07% of the company’s stock.
Haemonetics Trading Down 0.2%
Shares of NYSE HAE opened at $120.13 on Friday. Haemonetics Corporation has a 1-year low of $51.00 and a 1-year high of $132.00. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.84 and a quick ratio of 1.83. The business’s 50 day moving average is $115.20 and its two-hundred day moving average is $82.75. The stock has a market capitalization of $5.47 billion, a P/E ratio of 53.87, a PEG ratio of 2.40 and a beta of 0.63.
Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.06. The business had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a return on equity of 27.42% and a net margin of 7.52%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the company earned $1.27 EPS. As a group, research analysts expect that Haemonetics Corporation will post 5.32 EPS for the current year.
Haemonetics Company Profile
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Featured Articles
- Five stocks we like better than Haemonetics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
